Omadacycline mesylate  (Synonyms: PTK 0796 mesylate; Amadacycline mesylate)

Omadacycline (PTK 0796) mesylate, a first-in-class orally active aminomethylcycline antibacterial, is a member of the tetracycline class of antibiotics. Omadacycline mesylate acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline mesylate possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline mesylate can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections^[1][2][3][4].

Omadacycline displays activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), beta-hemolytic streptococci, penicillin-resistant Streptococcus pneumonia (PRSP) and Haemophilus influenzae (H. influenzae), with MIC₉₀s of 1.0, 0.25, 0.5, 0.25 and 2.0 μg/mL respectively^[2].
Omadacycline is active against strains expressing tetracycline and other antibiotics resistance by ribosomal protection and active tetracycline efflux^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Omadacycline (0.11-18 mg/kg; a single i.v.) exhibits efficacy against Streptococcus pneumonia, Escherichia coli, and Staphylococcus aureus in mice systemic infection model, with ED₅₀s ranging from 0.30 mg/kg to 3.39 mg/kg^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

652.76

Solid

C₃₀H₄₄N₄O₁₀S

1196800-40-4

CS(=O)(O)=O.O=C(C(C1=O)=C(O)[[email protected]@H](N(C)C)[[email protected]]2([H])C[[email protected]]3([H])CC4=C(C(C3=C(O)[[email protected]@]21O)=O)C(O)=C(CNCC(C)(C)C)C=C4N(C)C)N

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

• [1]. Durães F, et, al. Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines. Pharmaceuticals (Basel). 2019 Apr 21;12(2):63.  [Content Brief]

  [2]. Macone AB, et, al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58(2):1127-35.  [Content Brief]

  [3]. Zhanel GG, et, al. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. Drugs. 2020 Feb;80(3):285-313.  [Content Brief]

  [4]. Markham A, et, al. Omadacycline: First Global Approval. Drugs. 2018 Dec;78(18):1931-1937.  [Content Brief]